about
Analysis of heritability and shared heritability based on genome-wide association studies for thirteen cancer typesRelated F-box proteins control cell death in Caenorhabditis elegans and human lymphomaCooperative epigenetic modulation by cancer amplicon genesChronic active B-cell-receptor signalling in diffuse large B-cell lymphomaFrequent mutation of histone-modifying genes in non-Hodgkin lymphomaHVCN1 modulates BCR signal strength via regulation of BCR-dependent generation of reactive oxygen speciesMolecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathwaysMolecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphomaRole of the tumor microenvironment in mature B-cell lymphoid malignanciesThe use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma: a rare clinicopathologic entity with poor prognosis.Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin.Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma.Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma.Targeting Non-proteolytic Protein Ubiquitination for the Treatment of Diffuse Large B Cell LymphomaAberrant expression of T-plastin in Sezary cellsConfirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarrayLenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II studyA new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracyThe revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOPOncogenically active MYD88 mutations in human lymphomaMHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancersEtiologic heterogeneity among non-Hodgkin lymphoma subtypes: the InterLymph Non-Hodgkin Lymphoma Subtypes ProjectEZH2 and BCL6 Cooperate to Assemble CBX8-BCOR Complex to Repress Bivalent Promoters, Mediate Germinal Center Formation and LymphomagenesisCircos: an information aesthetic for comparative genomicsRituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402Fc Gamma Receptor 3A and 2A Polymorphisms Do Not Predict Response to Rituximab in Follicular LymphomaAnxiety and health-related quality of life among patients with low-tumor burden non-Hodgkin lymphoma randomly assigned to two different rituximab dosing regimens: results from ECOG trial E4402 (RESORT).Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402.Mantle cell lymphoma: report of the 2010 Mantle Cell Lymphoma Consortium Workshop.Multicolour fluorescence in situ hybridization analysis of t(14;18)-positive follicular lymphoma and correlation with gene expression data and clinical outcome.Genetic variation in the NBS1, MRE11, RAD50 and BLM genes and susceptibility to non-Hodgkin lymphoma.Delineation of a minimal region of deletion at 6q16.3 in follicular lymphoma and construction of a bacterial artificial chromosome contig spanning a 6-megabase region of 6q16-q21.Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project.A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172).Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404).Model-based clustering of array CGH data.De novo transcriptome assembly with ABySS.Per-channel basis normalization methods for flow cytometry data.
P50
Q24170413-0050D3EE-ACF3-4DCB-8D70-95577E789065Q24319026-4C5A72C9-F805-498E-99B2-61020223EEBBQ24608701-EB9DBECE-4D7C-47ED-928C-4CC9F61F7391Q24613755-34FCDC23-F667-428A-8AB4-83935AFA278BQ24630610-C95D10F2-21E1-4E8A-A192-66C0F5C4DFE2Q24632831-D71E7547-CC0A-4964-835D-3F023BB25FA8Q24652565-1BD7518B-0ADB-4BD4-A151-4B196F4C334FQ24672476-EE4FD4C2-2C7D-4177-BFA3-4BCC43BCABA9Q26748775-361E5BB3-1CEA-4095-8536-94C201BE6804Q27824784-FD76E656-FC04-4272-89D8-6854C7C82322Q27851477-752871B0-1EA4-44A9-B8A0-D6798949CB6FQ27851546-AB788ED7-C6F5-4D1E-A94F-A73C093D4945Q27851699-4D7E2311-091B-4BF4-9338-08EF12B28296Q27853195-5D051717-C54B-416F-BAA9-EDB458B1BBE6Q27853198-82E69FF8-6EA8-4723-98C3-39BCE56B650FQ28115962-217C16D3-C49E-4C5F-BA0D-1101D8D9069FQ28183483-2EEDFCFB-22B0-4756-B006-368662797A28Q28204313-AB22E89C-1F52-47CA-980A-5DBE820C0211Q28246277-CDFD3EDC-88AC-4D53-9154-19D2B2C2DD5CQ28256358-421D7CFE-C4D0-4C19-841B-1658418538A8Q28274089-B6BEAE7D-877A-4183-AF9D-2EEA27054AB1Q28301648-8B319E54-5174-492E-BB2A-4D653E6C2BE5Q28306431-E88E8502-B5D5-49EA-BE3D-4D5856F3C8BFQ28393769-6DB72A2C-DCC5-4871-9DF1-170B7C9B8762Q28771717-49B4A5C3-4DBC-48C1-AC64-298C177CA1AEQ29547653-74D368B5-6CB3-4D38-B65D-723A953F8F02Q30277158-240BF5BF-CB6B-4593-A1EB-FA7560C66954Q30278460-792F0B47-C094-42A7-AD1F-2243DCC0787BQ30300919-693641E1-E222-4707-8C15-CFE3316DEF75Q30370665-E1AF98AF-6067-4FF1-A46A-5F94D7DC4FAAQ30452448-45A59E49-3CD3-437B-BBDC-21D78F402023Q30819544-16FBCB16-4491-4E3B-B2A1-261D7C0818E3Q30886820-BFDD620C-EC64-47AB-BD7E-0EAC8FB23390Q33199914-4AF93ADE-CBD4-4396-9559-B61BBB725570Q33393849-E523BFB6-325A-48B4-8126-7214B0C2180CQ33394153-FE7619FF-018F-41CD-88E0-BD4E6632EA9FQ33408536-2A5E67BE-5291-4743-A207-977C0AF0BA7BQ33455313-CD09D18D-AF1E-4B57-9A14-C37D929D8429Q33467690-1F4F09E2-79C4-469E-87EE-40CE2D7420AFQ33515614-0DEF1AA7-2FEE-40D2-89D0-3ACA1BD2B7B7
P50
description
researcher
@en
wetenschapper
@nl
name
Randy D Gascoyne
@en
Randy D Gascoyne
@nl
type
label
Randy D Gascoyne
@en
Randy D Gascoyne
@nl
prefLabel
Randy D Gascoyne
@en
Randy D Gascoyne
@nl
P31
P496
0000-0002-2610-5690